• Home
• Introduction
• Vision & Future Directions
• Seminars
• News
  • Academic Positions Available
• Contact
• Alberta Health Services
• Tools
  • Google
  • U of C Home Page
  • My U of C Login
  • U of C Directory
  • Tools & Shortcuts

Dr. Oksana Suchowersky

BSc (Hon), MSc, MD, FRCPC, FCCMG
Adjunct Professor, Department of Medical Genetics
Adjunct Professor, Department of Clinical Neurosciences
Tel: (403) 220-6344
Fax: (403) 210-8119
E-mail:
website: http://medicalgenetics.ca

Research Interests

*Diagnostic predictors of Huntington disease
*Improving therapies for Parkinson disease and Huntington disease
*Neuroprotection for neuro degenerative disorders
*Hereditary spinocerebellar ataxias


Publications (selected from 23) 

Bombard Y, Penziner E, Decolongon J, Klimek M, Creighton S, Suchowersky O, Guttman M, Paulsen J, Bottorff J, and Hayden M.. Managing genetic discrimination: Strategies used by individuals found to have the Huntington disease mutation. Clin.Genet 2007;71(3):220-231.

 

Toth C, Dunham C, SuchowerskyO, et al. Unusual clinical, laboratory, and muscle histopathological findings in a family with myotonic dystrophy type 2. Muscle Nerve 2007 Feb;35(2):259-64.

 

Quickfall J, Suchowersky O, Pathological gambling associated with dopamine agonist use in restless legs syndromes. Parkinsonism Relat Disord. 2007 Dec;13(8):535-6.

 

Suchowersky O, The genetics of Parkinson disease: to test or not to test. Can J Neurol Sci. 2007 Aug;34(3):266-7.

 

Bombard Y, Penziner E, Suchowersky O, et al. Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. Eur J Hum Genet 2007 Oct 24:;[Epub ahead of print]

 

Han F, Racacho L, Yang H, Read T, Suchowersky O, et al. Large deletions account for an increasing number of mutations in SGCE. Mov Disord. 2007 Dec 20; [Epub ahead of print]

 

Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11;66(7):968-75.

 

Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):976-82.

 

Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, et al. Heterozygosity for parkin mutation influences onset age in familial Parkinson’s disease: The GenePD Study. Arch Neurol 2006 Jun;63(6):826-32.

 

Suchowersky O, Treatment of Parkinson’s Disease – where do we go from here? Nat Clin Pract Neurol 2006 Sep;2(9):461.

 

Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross CA, Margolis RL, Rosenblatt A, Squitieri F, Frati L, Gomez-Tortosa E, Garcia CA, Suchowersky O, et al.. Genome-wide significance for a modifier of age at neurological onset in Huntington’s disease at 6q23-24: the HD MAPS study. BMC Med Genet 2006 Aug 17;7:71.

 

Wilk JB, Tobin JE, Suchowersky O, et.al. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. Neurology 2006 Dec 26;67(12):2206-10.

 

Research Funding

 

NIH

CIHR

"The effect of music therapy on motor and non-motor symptoms in Parkinson's disease" 2006-2011